In this issue:
- Microplastics and nanoplastics in atheromas
- RNA interference agent zilebesiran for mild to moderate hypertension
- Recurrence of AF in patients with new- onset AF after CABG
- Cardiovascular outcomes in type 2 diabetics treated with various agents
- Direct oral anticoagulants for stroke prevention in patients with device- detected AF
- Angiotensin receptor + neprilysin inhibition in patients with STEMI vs NSTEMI
- Remoteness does not affect post-MI outcomes in Victoria
- Secondary prevention medications in metropolitan vs non-metropolitan areas of Victoria
- Concomitant use of SSRIs and oral anticoagulants increases risk of major bleeding
- Impact of empagliflozin on heart failure risk after MI